These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 34704527)

  • 41. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
    Charliński G; Vesole DH; Jurczyszyn A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular mechanisms of cereblon-based drugs.
    Asatsuma-Okumura T; Ito T; Handa H
    Pharmacol Ther; 2019 Oct; 202():132-139. PubMed ID: 31202702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4
    Yang SJ; Jeon S; Baek JW; Lee KM; Park CS
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
    Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
    Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
    Tao J; Yang J; Xu G
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
    Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.
    Heim C; Maiwald S; Steinebach C; Collins MK; Strope J; Chau CH; Figg WD; Gütschow M; Hartmann MD
    Biochem Biophys Res Commun; 2021 Jan; 534():67-72. PubMed ID: 33310190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
    Collins I; Wang H; Caldwell JJ; Chopra R
    Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
    Beedie SL; Huang PA; Harris EM; Strope JD; Mahony C; Chau CH; Vargesson N; Figg WD
    FASEB J; 2020 Sep; 34(9):11395-11404. PubMed ID: 32677118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
    Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
    Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.
    Sato T; Ito T; Handa H
    Front Cell Dev Biol; 2021; 9():629326. PubMed ID: 33777938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRBN ligand expansion for hematopoietic prostaglandin D
    Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
    Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.